首页> 美国卫生研究院文献>Wiley-Blackwell Online Open >Cardiovascular and kidney outcomes of linagliptin treatment in older people with type 2 diabetes and established cardiovascular disease and/or kidney disease: A prespecified subgroup analysis of the randomized placebo‐controlled CARMELINA® trial

【2h】

Cardiovascular and kidney outcomes of linagliptin treatment in older people with type 2 diabetes and established cardiovascular disease and/or kidney disease: A prespecified subgroup analysis of the randomized placebo‐controlled CARMELINA® trial

机译：利格列汀治疗2型糖尿病和已确定的心血管疾病和/或肾脏疾病的老年人的心血管和肾脏结局：随机安慰剂对照的CARMELINA®试验的预先确定的亚组分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

获取外文期刊封面目录资料

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

In CARMELINA®, linagliptin demonstrated cardiovascular and renal safety in patients with type 2 diabetes (T2D) with high renal and cardiovascular disease (CVD) risk. We investigated safety and efficacy of this dipeptidyl peptidase‐4 inhibitor in older participants.

机译：在CARMELINA®中，利格列汀对患有高肾脏和心血管疾病（CVD）风险的2型糖尿病（T2D）患者显示出心血管和肾脏安全性。我们研究了这种二肽基肽酶-4抑制剂在老年受试者中的安全性和有效性。

著录项

期刊名称 Wiley-Blackwell Online Open
作者
Mark E. Cooper; Julio Rosenstock; Takashi Kadowaki; Yutaka Seino; Christoph Wanner; Sven Schnaidt; Douglas Clark; Odd Erik Johansen; CARMELINA investigators;
展开▼
作者单位

展开▼
年(卷),期 -1(22),7
年度 -1
页码 -1
总页数 12
原文格式 PDF
正文语种
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial [J] . Diabetes care . 2020,第8期

机译：Linaglittin对正常和减少肾功能患者心血管和肾脏结果的影响：Carmelina随机试验的二次分析
2. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA ? ): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk [J] . Julio Rosenstock, Vlado Perkovic, John H. Alexander, Cardiovascular Diabetology . 2018,第1期

机译：LINAgliptin（CARMELINA？）进行心血管安全性和肾脏微血管结果研究的基本原理，设计和基线特征：一项针对2型糖尿病和高心脏肾脏风险患者的随机，双盲，安慰剂对照临床试验
3. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial [J] . Cherney David Z. I., Zinman Bernard, Inzucchi Silvio E., The lancet. Diabetes & endocrinology. . 2017,第8期

机译：Empagliflozin对2型糖尿病患者尿白霉素对肌酐比例的影响及成熟的心血管疾病：EMPA-REG结果随机，安慰剂对照试验的探索性分析
4. Low-cost detection of cardiovascular disease on chronic kidney disease and dialysis patients based on hybrid heterogeneous ECG features including T-wave alternans and heart rate variability [C] . Tsu-Wang Shen, Te-Chao Fang, Yi-Ling Ou, 2010 Computers in Cardiology . 2010

机译：基于混合异质ECG功能（包括T波交替蛋白和心率变异性）的低成本检测慢性肾脏病和透析患者的心血管疾病的方法
5. Life Course Evaluation of a Plant-Centered Diet and Risk of Type 2 Diabetes, Weight Gain, Cardiovascular Diseases, All-Cause Mortality, and Markers of Chronic Kidney Disease: The Coronary Artery Risk Development in Young Adults (Cardia) Cohort [D] . Choi, Yuni. 2021

机译：生命课程评估植物中心的饮食和2型糖尿病风险，体重增加，心血管疾病，慢性肾病的全因死亡率和标志性：年轻成年人的冠状动脉风险发展（Cardia）队列
6. Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and/or kidney disease: subgroup analysis of the randomized CARMELINA® trial [O] . Nobuya Inagaki, Wenying Yang, Hirotaka Watada, 2020

机译：Linagliptin和亚洲人的心肺成果患有2型糖尿病和成立的心血管和/或肾病：随机Carmelina®试验的亚组分析
7. Cardiovascular and kidney outcomes of linagliptin treatment in older people with type 2 diabetes and established cardiovascular disease and/or kidney disease: A prespecified subgroup analysis of the randomized, placebo‐controlled CARMELINA® trial [O] . Mark E. Cooper, Julio Rosenstock, Takashi Kadowaki, 2020

机译：患有2型糖尿病和肾脏疾病和/或肾病的老年人Linagliptin治疗的心血管和肾脏结果：随机安慰剂控制的Carmelina®试验的预先精确的亚组分析

Cardiovascular and kidney outcomes of linagliptin treatment in older people with type 2 diabetes and established cardiovascular disease and/or kidney disease: A prespecified subgroup analysis of the randomized placebo‐controlled CARMELINA® trial

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅